Evotec SE Files 6-K, Attaches Ad Hoc Announcement
Ticker: EVOTF · Form: 6-K · Filed: Nov 22, 2024 · CIK: 1412558
| Field | Detail |
|---|---|
| Company | Evotec Se (EVOTF) |
| Form Type | 6-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, ad-hoc-announcement
TL;DR
Evotec SE dropped an ad hoc announcement on 11/22/24, filing it with the SEC.
AI Summary
On November 22, 2024, Evotec SE issued an ad hoc announcement. The filing does not provide specific details about the announcement itself, only that it is attached as Exhibit 99.1.
Why It Matters
This filing indicates Evotec SE has made a significant announcement, which could impact investors' understanding of the company's current status or future plans.
Risk Assessment
Risk Level: low — The filing is a routine report of an ad hoc announcement and does not contain new financial information or significant operational updates.
Key Players & Entities
- Evotec SE (company) — Registrant
- November 22, 2024 (date) — Date of ad hoc announcement
- Exhibit 99.1 (document) — Attached announcement
FAQ
What is the subject of the ad hoc announcement filed by Evotec SE on November 22, 2024?
The filing does not specify the subject of the ad hoc announcement, only that it is attached as Exhibit 99.1.
What form type is this SEC filing?
This is a Form 6-K.
What is Evotec SE's primary business classification?
Evotec SE is classified under Pharmaceutical Preparations [2834].
Where is Evotec SE's principal executive office located?
Evotec SE's principal executive office is located at Essener Bogen 7, 22419 Hamburg, Germany.
Is Evotec SE required to file annual reports under Form 20-F or Form 40-F?
Evotec SE indicates it files annual reports under Form 20-F.
Filing Stats: 207 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-11-22 11:42:36
Filing Documents
- tm2429323d1_6k.htm (6-K) — 10KB
- tm2429323d1_ex99-1.htm (EX-99.1) — 3KB
- 0001104659-24-121952.txt ( ) — 14KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): On November 22, 2024, Evotec SE (the “Company”) issued an Ad hoc announcement. A copy of the Ad hoc announcement is attached as Exhibit 99.1 hereto. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Comment on withdrawn non-binding offer SIGNATURE Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Evotec SE By: /s/ Christian Wojczewski Name: Christian Wojczewski Title: Chief Executive Officer Date: November 22, 2024